Tag - shionogi

 
 

SHIONOGI

A health ministry panel has approved the messenger RNA vaccine Daichirona.
JAPAN / Science & Health
Aug 1, 2023
Japan panel endorses first domestically developed COVID vaccine
The shot is based on the original strain of the coronavirus, making it unlikely that it will be used in Japan or elsewhere.
Japan Times
BUSINESS / Companies
Feb 27, 2023
Shionogi sees COVID pill reaping $2 billion in annual sales upon U.S. approval
CEO Isao Teshirogi said he expects U.S. approval of the drug could come by the winter of 2024, pending a late-stage trial.
Japan Times
JAPAN / Science & Health
Feb 22, 2023
Shionogi says its drug Xocova may reduce risks of long COVID symptoms
For 14 major symptoms of COVID-19, 14.5% of those given Xocova reported at least one of the symptoms six months after the start of treatment, compared with 26.3% who were given a placebo.
Japan Times
BUSINESS / Companies
Jan 6, 2023
Shionogi's COVID-19 pill may get China approval in March
The Japanese drugmaker has been submitting data to regulators in China and expects Xocova to be authorized for use as early as this quarter, Chief Executive Officer Isao Teshirogi said.
Japan Times
JAPAN / Science & Health
Dec 13, 2022
Shionogi says Japan government to buy 1 million more COVID pill doses
The added supply agreement comes at a time when Japan is dealing with an eighth wave of COVID-19 infections.
Japan Times
JAPAN / Science & Health
Nov 24, 2022
Shionogi applies for COVID-19 vaccine approval, would be first Japan-made
The recombinant protein-based preventive vaccine is the same type as a COVID-19 vaccine developed by Novavax and differs from messenger RNA vaccines developed by Pfizer or Moderna.
Japan Times
JAPAN / Science & Health
Nov 22, 2022
Shionogi COVID-19 pill Xocova wins emergency approval in Japan
A course of Shionogiu2019s treatment consists of seven pills over five days u2014 significantly fewer than alternatives which require between 30 to 40 pills over the same period.
Japan Times
JAPAN / Science & Health
Sep 28, 2022
Shionogi says COVID-19 pill trial shows reduction in symptoms
The drug met the trial's goal of reducing five key symptoms of the omicron variant within 72 hours of onset, the company said.
Japan Times
JAPAN
Aug 10, 2022
Shionogi confirms efficacy of oral COVID drug for omicron subvariant
The announcement came after a health ministry panel in July postponed the granting of emergency approval for the drug.
Japan Times
JAPAN / Science & Health
Jul 20, 2022
Health ministry panel delays decision on emergency approval for Shionogi’s COVID pill
The delay is a blow to one of Japan's largest drugmakers and also raises questions about the process for drugs to gain fast-track approvals in times of emergency.
Japan Times
BUSINESS / FOCUS
May 3, 2022
Japanese firms turn to four-day week to improve work-life balance
Companies open to the arrangement are hoping staff will acquire new skills or develop a network of contacts through additional education or a second job.
Japan Times
BUSINESS / Companies
Apr 22, 2022
U.S. in talks with Japan's Shionogi to buy new COVID-19 pill
Shionogi's treatment is in late-stage clinical trials and hasnu2019t yet been authorized, but in earlier studies, it reduced viral loads in patients within the first few days of use.
Japan Times
JAPAN
Apr 13, 2022
Shionogi to recommend pregnant women not use oral COVID drug
Shionogi has filed for conditional early approval to skip the final stage of clinical trials once a certain level of efficacy and safety has been confirmed.
Japan Times
BUSINESS / Companies
Mar 25, 2022
Shionogi signs supply deal with Japanese government for COVID-19 pill
The government is considering buying a million doses of the drug, pending regulatory approval.
Japan Times
JAPAN / FOCUS
Mar 15, 2022
Japanese firms near domestic rollout of their COVID-19 vaccines
Several companies are expecting to introduce their shots in the coming fiscal year, a major step in Japan reducing its reliance on foreign vaccine manufacturers.
Japan Times
JAPAN
Mar 6, 2022
Shionogi says its COVID-19 shot is effective and safe
The positive data could mean Japan, which is racing to complete a booster drive in hopes of curbing future outbreaks, will soon have an indigenous jab.
Japan Times
JAPAN / Science & Health
Feb 25, 2022
Shionogi seeks approval for Japan’s first domestic COVID pill
Kishida has signaled that the central government will expedite the review process to pave the way for a swift approval if the drug's efficacy and safety are confirmed.
Japan Times
JAPAN / Science & Health
Feb 10, 2022
Shionogi and hospital to research development of nasal COVID-19 vaccine
The firm has also developed an oral COVID-19 vaccine and is expected to apply for approval as early as next week following clinical trials that showed its effectiveness.
Japan Times
JAPAN
Feb 8, 2022
Japan to consider early approval for Shionogi COVID-19 pill
The company could file for early approval of the drug as soon as next week, and it could deliver enough doses for 1 million people by the end of March.
Japan Times
BUSINESS
Dec 27, 2021
Tardy COVID-19 vaccine makers under fire for trials in developing nations
Vaccine developers at the testing phase now are seeking developing countries where vaccination rates remain low and the virus is still active.

Longform

Hideo Shimoju points to a possible site that his fellow neighbors may relocate to. Such relocations have happened before, but not preemptively.
In disaster-prone Japan, some communities consider major moves